Skip to NavigationSkip to content

Pharma manufacturing news in brief

Published on 11/12/12 at 10:18am

AMRI renews a key contract with GE, NextPharma sells off US unit Bioserv, plus facility updates for Sanner and Recipharm and a new drug delivery alliance between Hovione and Solvias.

AMRI has renewed its contract with GE Healthcare for the long-term supply of aminobisamide HCl, a compound used in the manufacture of diagnostic imaging agents. AMRI makes the ingredient at its large-scale manufacturing facility in Rensselaer, New York, and will continue to do so until the end of 2016 under the new agreement. The GE deal is the largest in AMRI's portfolio of commercial supply contracts. 

German plastic packaging and medical component specialist Sanner has said it will spend €4 million modernising its 30,000 sq. m. manufacturing facility in Bensheim to improve its efficiency and make it more environmentally-friendly. The revamp is expected to complete in June 2013, and will include a central transport corridor to improve the flow of goods as well as a technical services centre with a power/heat cogeneration system.

Swedish contract development and manufacturing organisation Recipharm is expanding its analytical services and stability studies facility in Solna so that the company can carry out more projects at the same time. The plant will be rebuilt to facilitate the expansion and will be online by May 2013. In addition to carrying out stability studies the facility works on new stability-indicating analytical methods, supply and execution of method transfer protocols, establishment of new product assay and degradation methods, graduated validation plans to suit the phase of drug development and cleaning validation, amongst other services.

Portugal-based pharma ingredients specialist Hovione has teamed up with Solvias of Switzerland on the development and GMP supply of pharmaceutical co-crystals. Hovione said the agreement strengthens its expertise in overcoming drug delivery challenges and also the supply of GMP materials from Phase I to commercial scale. The alliance combines Hovione's particle engineering technologies focused on amorphous solid dispersions, crystal design and reduction and control of particle size with Solvias' co-crystallisation expertise and capabilities. By working together the two companies will help customers to "overcome poor bioavailability and other drug delivery challenges". Financial terms were not disclosed.

NextPharma Technologies of the UK has completed the sale of its US contract manufacturing unit Bioserv to private equity firm KESA Partners as it focuses on its core businesses in penicillins, cephalosporins, sterile cytotoxics, non-cytotoxics and hormonal drugs. NextPharma said it will continue to expand its sales and marketing presence in North America and to develop long-term partnerships with North American customers. Bioserv was founded in 1988 as a small boutique contract manufacturing organisation providing Phase I-II production and fill and finish services, and has more than 35,000 sq. ft. of facility space.

Phil Taylor

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches